Imago Pharmaceuticals Inc.

Biopharma Acquisitions Biopharma merger and acquisition value for the fourth quarter of 2022 reached $35.7bn from 41 transactions, 21 of which had disclosed values. Making up 78% of the Q4 total was A

While consultancy PwC generally is bullish about increased deal-making and M&A activity by the biopharmaceutical sector in 2023, in a recent report it notes that the drug-pricing implications of last